IL234602B - Cancer treatment with rapamycin target site kinase inhibitors - Google Patents

Cancer treatment with rapamycin target site kinase inhibitors

Info

Publication number
IL234602B
IL234602B IL234602A IL23460214A IL234602B IL 234602 B IL234602 B IL 234602B IL 234602 A IL234602 A IL 234602A IL 23460214 A IL23460214 A IL 23460214A IL 234602 B IL234602 B IL 234602B
Authority
IL
Israel
Prior art keywords
cancer
treatment
kinase inhibitors
tor kinase
tor
Prior art date
Application number
IL234602A
Other languages
English (en)
Hebrew (he)
Other versions
IL234602A0 (en
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of IL234602A0 publication Critical patent/IL234602A0/en
Publication of IL234602B publication Critical patent/IL234602B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL234602A 2012-03-15 2014-09-11 Cancer treatment with rapamycin target site kinase inhibitors IL234602B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261611361P 2012-03-15 2012-03-15
US201261715323P 2012-10-18 2012-10-18
PCT/US2013/031206 WO2013138557A1 (en) 2012-03-15 2013-03-14 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
IL234602A0 IL234602A0 (en) 2014-11-30
IL234602B true IL234602B (en) 2020-05-31

Family

ID=48014336

Family Applications (1)

Application Number Title Priority Date Filing Date
IL234602A IL234602B (en) 2012-03-15 2014-09-11 Cancer treatment with rapamycin target site kinase inhibitors

Country Status (21)

Country Link
US (1) US20130245026A1 (cg-RX-API-DMAC7.html)
EP (1) EP2825170B1 (cg-RX-API-DMAC7.html)
JP (3) JP2015510891A (cg-RX-API-DMAC7.html)
KR (3) KR102122617B1 (cg-RX-API-DMAC7.html)
CN (2) CN104519885A (cg-RX-API-DMAC7.html)
AU (1) AU2013203153B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014022703A2 (cg-RX-API-DMAC7.html)
CA (1) CA2866872A1 (cg-RX-API-DMAC7.html)
EA (1) EA028414B1 (cg-RX-API-DMAC7.html)
ES (1) ES2677874T3 (cg-RX-API-DMAC7.html)
IL (1) IL234602B (cg-RX-API-DMAC7.html)
MX (1) MX360878B (cg-RX-API-DMAC7.html)
MY (1) MY174022A (cg-RX-API-DMAC7.html)
NI (1) NI201400111A (cg-RX-API-DMAC7.html)
NZ (1) NZ628416A (cg-RX-API-DMAC7.html)
PH (1) PH12014502029B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201405707XA (cg-RX-API-DMAC7.html)
TW (1) TWI583385B (cg-RX-API-DMAC7.html)
UA (1) UA114315C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013138557A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201406706B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
SG11201505446WA (en) 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2014172436A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
HK1221168A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法
US20140314673A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
CA2908742C (en) * 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
WO2014172425A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
EP3549940A1 (en) 2013-04-17 2019-10-09 Signal Pharmaceuticals, LLC Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
RU2474582C2 (ru) 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
WO2010022243A1 (en) * 2008-08-20 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chemoprevention of head and neck squamous cell carcinomas
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
US20120028972A1 (en) * 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
EA028414B1 (ru) * 2012-03-15 2017-11-30 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение рака ингибиторами tor киназы

Also Published As

Publication number Publication date
WO2013138557A1 (en) 2013-09-19
TW201343168A (zh) 2013-11-01
NI201400111A (es) 2015-01-15
AU2013203153B2 (en) 2015-09-03
BR112014022703A2 (pt) 2021-05-04
NZ628416A (en) 2016-04-29
JP2019108368A (ja) 2019-07-04
PH12014502029A1 (en) 2014-11-24
ZA201406706B (en) 2016-05-25
TWI583385B (zh) 2017-05-21
JP2021102637A (ja) 2021-07-15
KR20140138927A (ko) 2014-12-04
EA028414B1 (ru) 2017-11-30
EA201491699A1 (ru) 2015-02-27
CA2866872A1 (en) 2013-09-19
SG11201405707XA (en) 2014-10-30
HK1201750A1 (en) 2015-09-11
CN104519885A (zh) 2015-04-15
MX2014011077A (es) 2014-10-14
CN108992446A (zh) 2018-12-14
KR20200070416A (ko) 2020-06-17
JP2015510891A (ja) 2015-04-13
MY174022A (en) 2020-03-04
ES2677874T3 (es) 2018-08-07
KR102122617B1 (ko) 2020-06-12
EP2825170B1 (en) 2018-05-09
KR20210071101A (ko) 2021-06-15
EP2825170A1 (en) 2015-01-21
IL234602A0 (en) 2014-11-30
UA114315C2 (uk) 2017-05-25
AU2013203153A1 (en) 2013-10-03
PH12014502029B1 (en) 2014-11-24
US20130245026A1 (en) 2013-09-19
MX360878B (es) 2018-11-21

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
IL288181A (en) Cancer treatment methods
ZA201402771B (en) Treatment of cancer with tor kinase inhibitors
ZA201406708B (en) Treatment of cancer with tor kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
ZA201504577B (en) Treatment of cancer with heterocyclic inhibitors of glutaminase
EP2903644A4 (en) TREATMENT OF CANCER
ZA201503105B (en) Treatment of prostate cancer with tor kinase inhibitors
GB201217892D0 (en) Treatment of cancer
PL2817286T3 (pl) Inhibitory kinazy do leczenia raka
SG11201405621UA (en) Methods of treating cancer using aurora kinase inhibitors
GB201217890D0 (en) Treatment of cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
GB201208296D0 (en) Treatment of cancer
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer
AU2012905667A0 (en) Vaccines for treatment of cancer

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed